BRVE Stock Forecast & Price Target

Braveheart Bio is supported by a de-risked, one-asset HCM strategy built around BHB-1893, a clinically validated cardiac myosin inhibitor class with faster PK, lower accumulation, fewer drug-drug interaction concerns, and a potentially wider therapeutic window. Its phase 2 data are encouraging in both oHCM and nHCM, including about a 6-point placebo-adjusted KCCQ benefit at 12 weeks in nHCM, improvements in diastolic relaxation, and early reductions in LV mass and wall thickness, while the IPO raised about $440M to fund both global phase 3 programs through completion. The thesis is further strengthened by a large, underpenetrated HCM market, an estimated ~$3B in risk-adjusted peak sales across oHCM and nHCM, and multiple near-term readthroughs in 4Q26, 1H27, and 2H27 that could de-risk the 2028/2029 pivotal path.

Braveheart Bio is a clinical-stage, pre-revenue biotech with no product sales, so it will likely need additional financing and faces dilution risk before BHB-1893 can contribute meaningfully. Its thesis also rests on a small 12-week phase 2 dataset with encouraging KCCQ and remodeling signals, but the larger global phase 3 NOBLEHEART-HCM study must prove those effects persist across broader HCM populations. Commercially, the company faces meaningful uncertainty versus established cardiac myosin inhibitors, while regulatory risk remains high because the FDA has still required REMS programs for approved CMIs and may do the same for BHB-1893.